Pharmaceutical Corruption News ArticlesExcerpts of Key Pharmaceutical Corruption News Articles in Media
Fraudulent research regularly appears in the 30,000 scientific journals published worldwide, a former editor of the British Medical Journal (BMJ) said today. Even when journals discover that published research is fabricated or falsified they rarely retract the findings, according to Richard Smith, who was also chief executive of the BMJ publishing group. Writing in the latest edition of the Journal of the Royal Society of Medicine, Dr Smith called on editors to blow the whistle on bad research and to use their clout to pressure universities into taking action against dodgy researchers. The former BMJ editor said it was likely that research fraud was "equally common" in the 30,000 plus scientific journals across the globe but was "invariably covered up". His call for action comes in the wake of several high profile cases of fraudulent research, including the Korean scientist Hwang Woo-suk who fabricated stem cell research that it was claimed would open up new ways to treat diseases like Parkinson's. Dr Smith criticised the failure of scientific institutions, including universities, to discipline dodgy researchers even when alerted to problems by journals. "Few countries have measures in place to ensure research is carried out ethically," he said. "Most cases are not publicised. They are simply not recognised, covered up altogether or the guilty researcher is urged to retrain, move to another institution or retire from research."
Note: For reliable information on the collusion of industry, government, and research facilities who place profits above advances in public health: http://www.WantToKnow.info/healthcoverup
No one foresaw ... the shocking extent to which the internet would change the terms of trade between corporations and society. One of the world's largest drug companies [was] the first victim. Britain's GlaxoSmithKline, the world's second-largest pharma, denied any wrongdoing, but agreed to pay $2.5m ... for concealing evidence of its antidepressant Seroxat's potential for harming children, while doing them no measurable good. Infinitely more frightening ... this pharma had the backing of institutions that we, the public, rely on to protect us from poisoning by prescription. The Royal College of Psychiatrists had insisted only a year earlier that 'there is no evidence that antidepressant drugs can cause dependence syndromes'. It was really the internet that allowed public health activists to do an end run around GSK's and the medical authorities' denials of the drug's risks. An explosion of websites dedicated to vivid accounts of antidepressant reactions told these campaigners about hundreds of thousands affected by a problem that officially did not exist. Health activists in Britain and America have uncovered the core of pharma might. In both countries, clinical drug tests are paid for by the pharmas, who tweak the trials' design for the best possible results. Until recently, only the most favourable findings got published in the 20,000-odd biomedical journals, many of them dependent on pharmas for funding. The drugs are approved for marketing by regulators, whose salaries are mostly financed by the subjects of their evaluations. The medicines are then prescribed by doctors routinely courted with pharma gifts ... meant to persuade them to change their prescribing habits.
Note: For a two-page summary with lots more reliable information on major health cover-ups by a doctor who was editor-in-chief of one of the most pretigious medical journals in the world, click here.
Generic drugs are just as safe and effective as their brand-name counterparts but they cost only a fraction as much. That is because companies that produce the generic versions simply copy the formula developed by the drug’s inventor years before. While your drugstore charges you less for a generic drug than a brand name version, that price difference is nothing compared to the markup most druggists place on the generics. Your pharmacy most likely paid a wholesale price of only pennies for that generic medicine. They then charge you a markup of 3,000%, 4,000%, even 5,000% or more, pocketing most of your savings. Who’s paying sky-high prices? People who can least afford to get ripped off—the elderly, the unemployed, and everybody who has to pay for their prescription medicine out of their own pocket. At CVS the cost of generic Prozac is marked up at least 56 times what the drug cost wholesale. It is a 5,594% markup. And in our survey of more than a dozen popular generic drugs, CVS leads the pack with average markups of 1,436% Walgreen’s is not far behind at 1,341% and Rite Aid markups on generics average 1,183%. [WXYZ reporter] Steve Wilson took the issue to Kurt Proctor, Vice President of the Association of Chain Drug Stores. "Explain to me why it’s necessary to take an 82 cent product and mark it up to $46.69? You have to mark it up 5,500% to meet your costs to make a profit? This is really about greed, isn’t it?" asked Wilson. "It’s not about greed," responded Proctor. "That’s not accurate at all. That’s a misleading statement. What I hope you will focus on is making sure people use their medications correctly."
Note: This important exposure of price-gouging by pharmacies is still available at Web Archive (click on the link above for the complete article, which is well worth reading in its entirety), but for some reason has been taken down at WXYZ's website. Could it be someone doesn't want us to know about this?
It's been a mystery in Washington for weeks. Just before President Bush signed the homeland security bill into law an unknown member of Congress inserted a provision into the legislation that blocks lawsuits against the maker of a controversial vaccine preservative called "thimerosal," used in vaccines that are given to children. Drug giant Eli Lilly and Company makes thimerosal. It's the mercury in the preservative that many parents say causes autism in thousands of children. But nobody in Congress would admit to adding the provision, reports CBS News Correspondent Jim Acosta – until now. House Majority Leader Dick Armey tells CBS News he did it to keep vaccine-makers from going out of business under the weight of mounting lawsuits. "I did it and I'm proud of it," says Armey, R-Texas. "It's a matter of national security," Armey says. Because Armey is retiring at the end of the year, some say the outgoing majority leader is the perfect fall guy to take the heat and shield the White House from embarrassment.
Note: A Reuters article reports that the former head of the US's CDC was later named president of Merck's vaccine division with accompanying high salary. Could this be payoff for her support in suppressing studies that cast doubt on vaccines?
Do drugs really stop working after the date stamped on the bottle? Fifteen years ago, the U.S. military decided to find out. Sitting on a $1 billion stockpile of drugs and facing the daunting process of destroying and replacing its supply every two to three years, the military began a testing program to see if it could extend the life of its inventory. The testing, conducted by the U.S. Food and Drug Administration, ultimately covered more than 100 drugs, prescription and over-the-counter. The results ... show that about 90% of them were safe and effective far past their original expiration date, at least one for 15 years past it. The program's returns have been huge. The military from 1993 through 1998 spent about $3.9 million on testing and saved $263.4 million on drug expense. In light of these results, a former director of the testing program, Francis Flaherty, says he has concluded that expiration dates put on by manufacturers typically have no bearing on whether a drug is usable for longer. "Manufacturers put expiration dates on for marketing, rather than scientific, reasons," says Mr. Flaherty, a pharmacist at the FDA until his retirement last year. "They want turnover." Joel Davis, a former FDA expiration-date compliance chief, says that with a handful of exceptions - notably nitroglycerin, insulin and some liquid antibiotics - most drugs are probably as durable as those the agency has tested for the military. "Most drugs degrade very slowly," he says. "In all likelihood, you can take a product you have at home and keep it for many years." Drug-industry officials ... acknowledge that expiration dates have a commercial dimension.
Note: As the Wall Street Journal charges to view this article at the above link, you can view it free here. For lots more on how the pharmaceutical industry cares more about profits than your health, click here.
Regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken. The digital pill combines two existing products: the former blockbuster psychiatric medication Abilify - long used to treat schizophrenia and bipolar disorder - with a sensor tracking system first approved in 2012. Experts say the technology could be a useful tool, but it will also change how doctors relate to their patients as they’re able to see whether they are following instructions. The pill has not yet been shown to actually improve patients’ medication compliance, a feature insurers are likely to insist on before paying for the pill. Additionally, patients must be willing to allow their doctors and caregivers to access the digital information. The technology carries risks for patient privacy, too, if there are breaches of medical data or unauthorized use as a surveillance tool, said James Giordano, a professor of neurology at Georgetown University Medical Center. “Could this type of device be used for real-time surveillance? The answer is of course it could,” said Giordano. The new pill, Abilify MyCite, is embedded with a digital sensor that is activated by stomach fluids, sending a signal to a patch worn by the patient and notifying a digital smartphone app that the medication has been taken.
Note: In 2010, it was quietly reported that Novartis AG would be seeking regulatory approval for such "chip-in-a-pill technology". For more along these lines, see concise summaries of deeply revealing news articles on microchip implants and the disappearance of privacy.
The Food and Drug Administration (FDA) is often accused of serving industry at the expense of consumers. This week, [there are reports] of an institutionalized FDA spying program on its own scientists, lawmakers, reporters and academics that included an enemies list of "actors" and collaborators. "Devicegate" dates back at least to January 2009 when scientists ... wrote President Obama that top FDA managers "committed the most outrageous misconduct by ordering, coercing and intimidating FDA physicians and scientists to recommend approval, and then retaliating when the physicians and scientists refused to go along." Unsafe [medical] devices - including those that emit excessive radiation - were approved. For reporting the safety risks, the scientists became targets. Some lost their jobs. The ... reprisals against FDA device reviewers [did not surprise former FDA drug reviewer Ronald Kavanagh]. "After FDA management learned I had gone to Congress about certain issues, I found my office had been entered and my computer physically tampered with," [said Kavanagh]. "Then, after I openly reported irregularities in an antipsychotic drug review and FDA financial collusion with outsiders to ... the House Committee on Oversight and Government Reform, I was threatened with prison. The threats, however, can be much worse than prison. One manager threatened my children - who had just turned 4 and 7 years old - and ... I was afraid that I could be killed for talking to Congress and criminal investigators."
Note: Read more on how the FDA spied on whistle-blowing scientists to suppress safety concerns. For more along these lines, see concise summaries of deeply revealing news articles on corruption in government and in the scientific community.
FBI agents arrested former Insys Therapeutics CEO Michael Babich and five other former company executives on Thursday for allegedly bribing doctors to prescribe an extremely addictive opioid painkiller to patients who didn’t need it. The Department of Justice (DOJ) alleges that the executives took part in a “nationwide conspiracy” to give healthcare providers kickbacks in exchange for the improper prescribing of Subsys - an opioid medication containing the highly addictive substance fentanyl, which is considered even more dangerous than painkillers like Vicodin. Subsys is meant to provide pain relief to cancer patients who are going through particularly excruciating pain episodes. It’s reserved for these neediest of patients due to its potency and addictive qualities. But federal prosecutors allege that Babich and his co-conspirators doled out kickbacks to doctors who prescribed the drug even to non-cancer patients, and even set up a special “reimbursement unit” to sway insurance companies and pharmacy benefits managers to provide coverage for these non-authorized uses. The charges range from racketeering to conspiracy to mail and wire fraud. The FBI’s actions come in the wake of a newly invigorated federal effort to tackle the prescription painkiller epidemic, which has claimed the lives of more than 165,000 Americans since 1999.
Note: These charges come on the heels of an ex-DEA official's public accusation that Congress has been helping drug makers avoid responsibility for their role in the US opioid epidemic. How many deaths and ruined lives are being caused by greedy executives and the politicians in their pockets? For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
Sugar pills worked as well at preventing kids' migraines as two commonly used headache medicines, but had fewer side effects, in a study that may lead doctors to rethink how they treat a common ailment in children and teens. It's the first rigorous head-to-head test in kids of two generic prescription drugs also used for adults' migraines: topiramate, an anti-seizure medicine, and amitriptyline, an anti-depressant. The idea was to see if either drug could reduce by half the number of days kids had migraines over a month's time. Both drugs worked that well - but so did placebo sugar pills. The results "really challenge what is typical practice today by headache specialists," said study author Scott Powers, a psychologist at Cincinnati Children's Hospital. "The fact that it shows that two of the most commonly used medications are no more effective than a placebo and have adverse effects makes a very clear statement," said Dr. Leon Epstein, neurology chief at Ann & Robert Lurie H. Children's Hospital of Chicago. The only government-approved migraine medication for kids is topiramate. Side effects from the drugs [included] fatigue, dry mouth and forgetfulness. Kids on topiramate also had tingling sensations in their hands, arms, legs or feet. There was one suicide attempt in the topiramate group, another known side-effect of that drug. The side effects were not unexpected, but given the risks, the results suggest the drugs shouldn't be "first-line prevention treatments" for kids' migraines, Powers said.
Note: This study was published in the New England Journal of Medicine. For more, see this mercola.com article. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources.
Using the playbook of Mylan, Turing and, well, their own company, Valeant Pharmaceuticals has hiked the price of yet another life-saving treatment to astronomical values. This time, it’s calcium EDTA, a lead poisoning treatment that cost US hospitals and poison control centers about $500 for a packet of six ampules (6 grams) before 2012, when Valeant acquired the drug. Poison control experts now say that US centers pay about $5000 per gram for the drug, compared to $15 per gram for Canadians. In a 6-year period ... Valeant increased the US price of the drug by as much as 7200%. Two physicians - Michael Kosnett from the University of Colorado School of Medicine and Timur Durrani at the University of California, San Francisco (UCSF) - expressed their concerns about these price hikes in a letter to U.S. Rep. Elijah Cummings (D-Md), the ranking member of the House Committee on Oversight and Government Reform. According to Kosnett and Durrani, the average price per milliliter for the drug went from $18.57 in 2008 to $1346.37 in 2014. U.S. hospitals have no other source for calcium EDTA. Most of those who develop acute lead poisoning are children. The effects of lead poisoning are lasting and profound. Calcium EDTA is on the World Health Organization’s Model List of Essential Medicines, which lists medications that are most critical for a healthcare system to have on hand.
Note: For more along these lines, see concise summaries of deeply revealing Big Pharma corruption news articles from reliable major media sources.
EpiPen prices aren't the only thing to jump at Mylan. Executive salaries have also seen a stratospheric uptick. Proxy filings show that from 2007 to 2015, Mylan CEO Heather Bresch's total compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, the company raised EpiPen prices, with the average wholesale price going from $56.64 to $317.82, a 461 percent increase. In 2007 the company bought the rights to EpiPen, a device used to provide emergency epinephrine to stop a potentially fatal allergic reaction and began raising its price. In 2008 and 2009, Mylan raised the price by 5 percent. At the end of 2009 it tried out a 19 percent hike. The years 2010-2013 saw a succession of 10 percent price hikes. And from the fourth quarter of 2013 to the second quarter of 2016, Mylan steadily raised EpiPen prices 15 percent every other quarter. After Mylan acquired EpiPen the company also amped up its lobbying efforts. In 2008, its reported spending on lobbying went from $270,000 to $1.2 million, according to opensecrets.org. Legislation that enhanced its bottom line followed, with the FDA changing its recommendations in 2010 that two EpiPens be sold in a package instead of one. And in 2013 the government passed a law to give block grants to states that required they be stocked in public schools.
A safeguard for Medicare beneficiaries has become a way for drugmakers to get paid billions of dollars for pricey medications at taxpayer expense. The cost of Medicare’s “catastrophic” prescription coverage jumped by 85 percent in three years, from $27.7 billion in 2013 to $51.3 billion in 2015. Out of some 2,750 drugs covered by Medicare’s Part D benefit, two pills for hepatitis C infection - Harvoni and Sovaldi - accounted for nearly $7.5 billion in catastrophic drug costs in 2015. Medicare’s catastrophic coverage was originally designed to protect seniors with multiple chronic conditions from the cumulatively high costs of taking many different pills. Beneficiaries pay 5 percent after they have spent $4,850 of their own money. With some drugs now costing more than $1,000 per pill, that threshold can be crossed quickly. Lawmakers who created Part D in 2003 also hoped added protection would entice insurers to participate in the program. Medicare pays 80 percent of the cost of drugs above a catastrophic threshold that combines spending by the beneficiary and the insurer. That means taxpayers, not insurers, bear the exposure for the most expensive patients. Catastrophic spending accounts for a fast-growing share of Medicare’s drug costs, which totaled nearly $137 billion in 2015. The catastrophic share was 37 percent, yet only about 9 percent of beneficiaries reached the threshold for such costs. Catastrophic coverage will soon cost as much as the entire prescription program did when it launched. Experts say the rapid rise in spending for pricey drugs threatens to make the popular prescription benefit financially unsustainable.
Note: Read an excellent essay by former New England Journal of Medicine editor Dr. Marcia Angell exposing The Truth About the Drug Companies. For more along these lines, see concise summaries of deeply revealing Big Pharma profiteering news articles from reliable major media sources.
Cholesterol does not cause heart disease in the elderly and trying to reduce it with drugs like statins is a waste of time, an international group of experts has claimed. A review of research involving nearly 70,000 people found there was no link between what has traditionally been considered “bad” cholesterol and the premature deaths of over 60-year-olds from cardiovascular disease. Published in the BMJ Open journal, the new study found that 92 percent of people with a high cholesterol level lived longer. The authors have called for a re-evaluation of the guidelines for the prevention of cardiovascular disease and atherosclerosis, a hardening and narrowing of the arteries, because “the benefits from statin treatment have been exaggerated”. Co-author of the study Dr Malcolm Kendrick, an intermediate care GP, acknowledged the findings would cause controversy but defended them as “robust” and “thoroughly reviewed”. Vascular and endovascular surgery expert Professor Sherif Sultan from the University of Ireland, who also worked on the study, said cholesterol is one of the “most vital” molecules in the body and prevents infection, cancer, muscle pain and other conditions in elderly people. “Lowering cholesterol with medications for primary cardiovascular prevention in those aged over 60 is a total waste of time and resources, whereas altering your lifestyle is the single most important way to achieve a good quality of life,” he said.
Note: Big Pharma was heavily involved in clinical trials of statins. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.
Genentech and another drugmaker will pay $67 million to settle claims that they misled doctors into prescribing a treatment to lung cancer patients for whom the companies knew it would not work. As a result, some patients may have died earlier than they would have if they had taken more effective drugs, a lawsuit brought by a former Genentech employee and joined by federal prosecutors alleges. From 2006 to 2011 Genentech and its marketing partner OSI Pharmaceuticals promoted Tarceva to treat all patients with non-small-cell lung cancer even though studies had shown that it worked for just those who had never smoked or had a certain gene mutation known as EGFR. Epidermal growth factor receptor is a type of protein found on the surface of cells in the body. The whistle-blower lawsuit was filed in 2011 by Brian Shields, who worked as a Tarceva sales representative and then a product manager. The lawsuit said the companies ... discouraged doctors from testing patients for EGFR. The companies also promoted Tarceva ... by giving doctors illegal kickbacks disguised as fees for making speeches or serving on Genentech’s advisory boards. Sales representatives across the country were “instructed to spend lavishly” on physicians, the case said, and given “an unlimited budget to wine and dine.” Genentech also organized lunches or dinners for lung cancer patients where “patient ambassadors” were paid fees to speak about how Tarceva could be used in ways never approved by regulators, the lawsuit said.
Note: While Genentech was inaccurately describing its new drugs to doctors and patients, this company was also fiercely lobbying to prevent others from selling affordable alternatives to its costly drugs. Practices like this, along with the suppression of promising cancer research, show how Big Pharma puts profit before people.
More than a decade ago, researchers at Gilead Sciences thought they had a breakthrough: a new version of the company’s key HIV medicine that was less toxic to kidneys and bones. Clinical trials ... seemed to support their optimism. Patients needed just a fraction of the dose, creating the chance of far fewer dangerous side effects. But in 2004 ... Gilead executives stopped the research. The results of the early patient studies would go unpublished for years as the original medication - tenofovir - became one of the world’s most-prescribed drugs for HIV, with $11 billion in annual sales. In 2010, Gilead restarted those trials. A year of treatment with Gilead’s HIV medicines costs about $30,000. Earlier this year, the Los Angeles-based AIDS Healthcare Foundation, which operates clinics and pharmacies for AIDS patients, sued Gilead, contending that it delayed the less toxic form of tenofovir to manipulate the patent system and keep prices artificially high. Animal studies showed that [tenofovir] could cause damage to the kidneys and bones. When the drug was approved in 2001, the FDA required Gilead to study whether the medicine would harm humans in the same way. [By] 2003, the company had received so many reports of patients experiencing kidney failure and other ... problems that it placed a warning on the drug’s label. Several times, U.S. regulators formally warned Gilead that it was downplaying the drug’s risks.
Note: After the FDA warned Gilead that its sales reps were illegally lying to doctors about tenofovir's safety, Gilead continued misrepresenting this drug, prompting the FDC to send the company a rare second warning letter. For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.
Antibiotic-resistant bacteria has been a growing concern in the United States, leading to thousands of deaths each year. Doctors prescribing antibiotics unnecessarily is a big contributor to the problem, and now a new analysis of government data [has] found that an estimated 30 percent of outpatient oral antibiotic prescriptions in the U.S. from 2010 to 2011 may have been unwarranted. According to the Centers for Disease Control and Prevention, antibiotic-resistant infections affect 2 million people and lead to about 23,000 deaths annually. "Antibiotic resistance is one of the most urgent public health threats of our time," Dr. Katherine E. Fleming-Dutra, of the CDC, told CBS News. "The use of antibiotics is the single most important factor leading to resistance." For the study, Fleming-Dutra and her team analyzed two CDC national surveys. The results showed that about half of the antibiotics prescribed for acute respiratory infections, including the common cold, bronchitis, and viral sore throat, may have been unnecessary. Across all conditions, about 30 percent of antibiotic prescriptions were inappropriate from 2010 to 2011. "This equates to about 47 million unnecessary antibiotic prescriptions written every year in the United States," Fleming-Dutra said. The strategy to improve outpatient antibiotic prescribing is twofold. Doctors need to be more cautious about prescribing antibiotics unnecessarily. Patients can play a role in stopping antibiotic misuse, too, [by expressing] their concerns about antibiotic overuse to their clinicians.
Note: Big Pharma profits handsomely from unnecessary drug prescriptions. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.
Dr Aseem Malhotra, an NHS cardiologist and a trustee of the King’s Fund health think tank, claims there is “a systemic lack of transparency in the information being given to doctors to prescribe medication, in terms of the benefits of drugs being grossly exaggerated and their side effects under reported in studies”. Dr Malhotra said the prevalence of pharmaceutical companies, which are “profit making businesses” being able to fund studies and drug trials causes biased information to be recorded and reported on in medical journals. This is in turn “creating an epidemic of misinformed doctors,” he said. This lack of transparency ... harms patients through the adverse side effects of drugs, Dr Malhotra said, citing an FDA report that found adverse events from prescribed medications caused 123,000 deaths in the USA in 2014 and 800,000 serious patient outcomes, which include hospitalisation or potentially causing disability. The FDA report also states that the number of adverse events from prescribed medications have tripled in the past 10 years in America. While the UK does not have the same kind of data, Peter Gotze, professor of research design at the University of Copenhagen, has evidence to suggest that prescribed drugs are the third biggest killer behind heart disease and cancer. Last year the Academy of Medical Royal Colleges launched a campaign to stop doctors from ‘over-treating’ patients.
Note: The editor of The Lancet, one of the most prestigious medical journals in the world, recently wrote that half of all claims made in medical science journals may be untrue. For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.
Bill and Melinda Gates are facing calls for their philanthropic Foundation, through which they have donated billions worldwide, to be subject to an international investigation. The Gates Foundation is about benefiting big business, especially in agriculture and health, through its “ideological commitment to promote neoliberal economic policies and corporate globalisation,” according to [a] report published by the campaign group Global Justice Now. The report accuses the Gates Foundation of [turning] “basic needs into commodities controlled by the market.” The report is critical of the close working relations between the Foundation and major international pharmaceutical corporations. It accuses the Gates Foundation of promoting specific priorities through agriculture grants, some of which undermine the interests of small farmers. These include promoting industrial agriculture, use of chemical fertilisers and expensive, patented seeds, and a focus on genetically modified seeds. The criticism echoes the accusations made by the Indian scientist Vandana Shiva who called the Gates Foundation the “greatest threat to farmers in the developing world.” The Foundation’s emphasis on “technological solutions” often ignores real solutions involving social and economic justice. “This cannot be given by donors in the form of a climate-resilient crop or cheaper smartphone, but must be about systemic social, economic and political change – issues not represented in the foundation’s funding priorities.”
Note: The Gates Foundation is heavily invested in GMO giants like Monsanto. It also provided $5 million to Oxitec, a company criticized for secretly releasing GM mosquitoes into the wild in 2009. Oxitec was purchased last August by biotech giant Intrexon for $160 million. By December, the Zika virus was all over the news and Intrexon was ramping up production of these GM insects to "fight Zika" in Brazil. For more along these lines, see concise summaries of deeply revealing corporate corruption news articles from reliable major media sources.
After Martin Shkreli raised the price of anti-parasitic drug Daraprim more than 50-fold to $750 a pill last year, he said he wasn’t alone in taking big price hikes. The former drug executive was right. A survey of about 3,000 brand-name prescription drugs found that prices more than doubled for 60 and at least quadrupled for 20 since December 2014. Skyrocketing prices are getting increased scrutiny ahead of a U.S. congressional hearing this week: Democratic Representative Elijah Cummings, ranking member on a committee that is probing drug pricing, said Tuesday that pricing “tactics are not limited to a few ‘bad apples,’ but are prominent throughout the industry.” The cost of many drugs [rises] at annual rates of more than 10 percent. Drugmakers raised the prices of products as wide-ranging as erectile dysfunction drug Viagra, heart treatments, dermatology medicine and even brands that long have lost their patents. While specialty companies have had the steepest hikes, giants such as Pfizer Inc. and GlaxoSmithKline Plc kept pushing through smaller rises. About 400 formulations of brand-name drugs went up at least 9.9 percent since early December. Valeant Pharmaceuticals International Inc., which in recent months has been under fire for its pricing was among the most aggressive, with 13 drugs that doubled or more since December 2014.
Note: For more excellent information on drug prices hikes, read this penetrating article in the Daily Beast. For more along these lines, see concise summaries of deeply revealing big pharma profiteering news articles from reliable major media sources.
Women who took antidepressants in the last six months of pregnancy were 87% more likely to have a child later diagnosed with autism. Doctors saw no increase in autism rates in women who took medication for depression in the first three months of pregnancy, according to [a new] study, published online Monday in JAMA Pediatrics. In the U.S., about 2.2% of children ages 3 to 17 - about one in 45 - have autism, according to the Center for Disease Control and Prevention's National Health Interview Survey, conducted in 2014. Women who took a specific type of antidepressants, called selective serotonin re-uptake inhibitors, or SSRIs, had more than double the risk of having a child with autism. Women who took more than one medication for depression ... were four times as likely to have a child with autism. The new study is ... part of a growing body of research that suggests that the events that cause autism largely occur before birth. Studies have found that children are at higher risk for autism, for example, if they are born early or very small. Children are also at higher risk if they are in medical distress during delivery; if they have older mothers or fathers; or if they are born less than a year after an older sibling.
Note: For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.
Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.